Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma

Histopathology

Volumn 41, Issue 4, 2002, Pages 322-330

  Moller M B ^a,b   Nielsen, O ^a   Pedersen, N T ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cyclin D3; MDM2; Non Hodgkin's lymphoma; p27Kip1; p53; Progression; Relapse; Transformation

Indexed keywords

CYCLIN D3; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; TUMOR BIOPSY; TUMOR DIAGNOSIS; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DISEASE PROGRESSION; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MALE; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 17144460571     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2002.01506.x     Document Type: Article

References (37)

1. Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1973-1998. Bethesda: National Cancer Institute, 2001.
2. Acker B, Hoppe RT, Colby TV et al. Histologic conversion in the non-Hodgkin's lymphomas. J. Clin. Oncol. 1983; 1; 11-16.
3. Sander CA, Yano T, Clark HM et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82; 1994-2004.
4. Lo Coco F, Gaidano G, Louie DC et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82; 2289-2295.
5. INK4agene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91; 2977-2984.
6. Elenitoba-Johnson KSJ, Gascoyne RD, Lim MS et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91; 4677-4685.
7. Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated bcl-2 gene. Blood 1996; 88; 3937-3944.
8. Gaidano G, Ballerini P, Gong JZ et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 1991; 88; 5413-5417.
9. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 1995; 86; 4587-4593.
10. Greiner TC, Moynihan MJ, Chan WC et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87; 4302-4310.
11. Møller MB, Gerdes A-M, Skjødt K, Mortensen LS, Pedersen NT. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 1999; 5; 1085-1091.
12. Møller MB, Nielsen O, Pedersen NT. Oncoprotein MDM2 over-expression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod. Pathol. 1999; 12; 1010-1016.
13. Kip1. Br. J. Haematol. 1999; 105; 730-736.
14. Møller MB, Nielsen O, Pedersen NT. Cyclin D3 expression in non-Hodgkin lymphoma: Correlation with other cell cycle regulators and clinical features. Am. J. Clin. Pathol. 2001; 115; 404-412.
15. Haupt Y, Maya R., Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387; 296-299.
16. Sun PQ, Dong P, Dai K, Hannon GJ, Beach D. p53-independent role of MDM2 in TGF-β1 resistance. Science 1998; 282; 2270-2272.
17. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78; 59-66.
18. Matsushime H, Quelle DE, Shurtleff SA et al. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 1994; 14; 2066-2076.
19. 1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 1994; 14; 2077-2086.
20. Møller MB, Ino Y, Gerdes A-M et al. Aberrations of the p53 pathway components p53, MDM2, and CDKN2A appear independent in diffuse large B-cell lymphoma. Leukemia 1999; 13; 453-459.
21. Wilson WH, Teruya-Feldstein J, Fest T et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89; 601-609.
22. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358; 80-83.
23. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993; 12; 461-468.
24. Landers JE, Haines DS, Strauss JFI, George DL. Enhanced translation. A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994; 9; 2745-2750.
25. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92; 725-734.
26. Cesarman E, Liu YF, Knowles DM. The MDM2 oncogene is rarely amplified in human lymphoid tumors and does not correlate with p53 gene expression. Int. J. Cancer 1994; 56; 457-458.
27. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 1998; 95; 15608-15612.
28. Yunis JJ, Frizzera G, Oken MM et al. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N. Engl. J. Med. 1987; 316; 79-84.
29. Armitage JO, Sanger WG, Weisenburger DD et al. Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin's lymphomas bearing t(14;18)(q32;q21). J. Natl. Cancer Inst. 1988; 80; 576-580.
30. Dierlamm J, Wlodarska I, Michaux L et al. FISH identifies different types of duplications with 12q13-15 as the commonly involved segment in B-cell lymphoproliferative malignancies characterized by partial trisomy 12. Genes Chromosomes Cancer 1997; 20; 155-166.
31. Alkhalaf M, Ganguli G, Messaddeq N, Le Meur M, Wasylyk B. MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice. Oncogene 1999; 18; 1419-1434.
32. Xiao Z-X, Chen J, Levine AJ et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375; 694-698.
33. Wang XQ, Ongkeko WM, Lau AWS, Leung KM, Poon RYC. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 2001; 61; 1598-1603.
34. Bentz M, Werner CA, Döhner H et al. High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood 1996; 88; 1437-1444.
35. Sonoki T, Harder L, Horsman DE et al. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood 2001; 98; 2837-2844.
36. Filipits M, Jaeger U, Pohl G et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin. Cancer Res. 2002; 8; 729-733.
37. Sanchez-Beato M, Camacho FI, Martinez-Montero JC et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 1999; 94; 765-772.